ARCT
Arcturus Therapeutics Holdings Inc.
There isn't enough reported data to score ARCT yet.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ARCT Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Strong |
ARCT's balance sheet is currently strong, but its revenue, profitability and cash flow are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ARCT PE Valuation
ARCT has no meaningful PE right now: it lost money over the past year.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ARCT Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ARCT's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ARCT Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.10 | -$0.65 |
| Q2 2026 | -$3.33 | -$1.11 |
| Q1 2026 | -$2.83 | -$0.31 |
| Q4 2025 | -$2.40 | +$0.60 |
| Q3 2025 | -$2.45 | -$0.15 |
| Q2 2025 | -$2.22 | +$0.43 |
| Q1 2025 | -$2.52 | +$1.47 |
| Q4 2024 | -$3.00 | -$1.88 |
ARCT is still losing money, but far less than before: $3.10 per share over the past year, against $7.74 at its worst in late 2021.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over ARCT on earnings, with more consistent year-over-year improvement.
ARCT Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $18.3M | +6.7% |
| Q2 2026 | $3M | -90% |
| Q1 2026 | $2.1M | -93% |
| Q4 2025 | $7.2M | -68% |
| Q3 2025 | $17.2M | -59% |
| Q2 2025 | $28.3M | -43% |
| Q1 2025 | $29.4M | -23% |
| Q4 2024 | $22.8M | -26% |
ARCT's revenue is recovering but still below its 2022 peak: $18M last quarter, up 6.7% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -50% | +46 points |
| Q2 2026 | -863% | -822 points |
| Q1 2026 | -1404% | -1347 points |
| Q4 2025 | -435% | -288 points |
| Q3 2025 | -96% | -71 points |
| Q2 2025 | -41% | +1.3 points |
| Q1 2025 | -57% | +23 points |
| Q4 2024 | -147% | -88 points |
ARCT's operating margin was −50% last quarter, up 46 points from the same quarter a year ago.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ARCT on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over ARCT on profitability, with a higher operating margin.
ARCT Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7M | +$10.4M |
| Q2 2026 | -$19.9M | -$14.2M |
| Q1 2026 | -$19.4M | +$15.8M |
| Q4 2025 | -$16.1M | -$15.9M |
| Q3 2025 | -$17.3M | +$6.5M |
| Q2 2025 | -$5.8M | +$24.7M |
| Q1 2025 | -$35.3M | -$29.5M |
| Q4 2024 | -$284K | +$1.2M |
ARCT has burned cash in almost every quarter: −$62M over the past year, against −$59M the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ARCT on cash generation, producing positive trailing cash flow while its opponent burns cash.
ARCT Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +17K shares |
| 1 year | +4.6% | +1.3M shares |
| 3 years | +5% | +1.3M shares |
| 5 years | +14% | +3.6M shares |
ARCT has 28M diluted shares, up 4.6% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ARCT on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ARCT Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2023 | -4.6x | Net Cash |
| Q4 2022 | -24.1x | Net Cash |
ARCT has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ARCT Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.7 | Neutral |
| Stochastic | 31.9 | Neutral |
ARCT's weekly RSI is 44 (neutral) and its Stochastic is 32 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ARCT PE vs Healthcare Sector
| Metric | ARCT | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
ARCT has no meaningful PE right now: it lost money over the past year.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ARCT Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.3 | 26% below |
| 20 week MA | $10.7 | 21% below |
| 50 week MA | $8.73 | 3.3% below |
| 100 week MA | $11.6 | 27% below |
| 200 week MA | $18.8 | 55% below |
ARCT is in a downtrend: it's below all five of its weekly moving averages, and 55% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ARCT Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $11.5 | $98.1 | +756% |
| 2021 | $98.1 | $39.9 | -59% |
| 2022 | $39.9 | $17.3 | -57% |
| 2023 | $17.3 | $31.5 | +83% |
| 2024 | $31.5 | $17.0 | -46% |
| 2025 | $17.0 | $6.16 | -64% |
| 2026 YTD | $6.16 | $8.44 | +37% |
ARCT has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.